Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.

Literature DB >> 27162469

Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.

Donald Moore.

Abstract

Entities: Disease

Year: 2016 PMID： 27162469 PMCID： PMC4849337

Source DB: PubMed Journal: P T ISSN： 1052-1372

× No keyword cloud information.

14 in total

1. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Authors: Jeffrey L Wolf; David Siegel; Hartmut Goldschmidt; Katharine Hazell; Priscille M Bourquelot; Bourras R Bengoudifa; Jeffrey Matous; Ravi Vij; Margarida de Magalhaes-Silverman; Rafat Abonour; Kenneth C Anderson; Sagar Lonial
Journal: Leuk Lymphoma Date: 2012-03-01

Review 2. Multiple myeloma: biology of the disease.

Authors: Anuj Mahindra; Teru Hideshima; Kenneth C Anderson
Journal: Blood Rev Date: 2010-11 Impact factor: 8.250

3. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors: Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal: Blood Date: 2006-05-25 Impact factor: 22.113

Review 4. Multiple myeloma.

Authors: Antonio Palumbo; Kenneth Anderson
Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245

5. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Authors: Meletios Dimopoulos; David S Siegel; Sagar Lonial; Junyuan Qi; Roman Hajek; Thierry Facon; Laura Rosinol; Catherine Williams; Hilary Blacklock; Hartmut Goldschmidt; Vania Hungria; Andrew Spencer; Antonio Palumbo; Thorsten Graef; Joseph E Eid; Jennifer Houp; Linda Sun; Scott Vuocolo; Kenneth C Anderson
Journal: Lancet Oncol Date: 2013-09-19 Impact factor: 41.316

6. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors: Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal: Blood Date: 2013-08-15 Impact factor: 22.113

7. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

Authors: V Eleutherakis-Papaiakovou; A Bamias; D Gika; A Simeonidis; A Pouli; A Anagnostopoulos; E Michali; T Economopoulos; K Zervas; M A Dimopoulos
Journal: Leuk Lymphoma Date: 2007-02

8. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors: Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal: Haematologica Date: 2009-11-30 Impact factor: 9.941

9. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

Authors: Donna M Weber; Thorsten Graef; Mohamad Hussein; Ronald M Sobecks; Gary J Schiller; Lisa Lupinacci; James S Hardwick; Sundar Jagannath
Journal: Clin Lymphoma Myeloma Leuk Date: 2012-10

10. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors: Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal: Lancet Oncol Date: 2014-09-18 Impact factor: 41.316

18 in total

1. Development of a Novel, Small-Molecule Brain-Penetrant Histone Deacetylase Inhibitor That Enhances Spatial Memory Formation in Mice.

Authors: Jawad B Belayet; Sarah Beamish; Mizzanoor Rahaman; Samer Alanani; Rajdeep S Virdi; David N Frick; A F M Towheedur Rahman; Joseph S Ulicki; Sreya Biswas; Leggy A Arnold; M S Rashid Roni; Eric Y Cheng; Douglas A Steeber; Karyn M Frick; M Mahmun Hossain
Journal: J Med Chem Date: 2022-02-08 Impact factor: 8.039

Review 2. Histone modifiers at the crossroads of oncolytic and oncogenic viruses.

Authors: Sara A Murphy; Norman John Mapes; Devika Dua; Balveen Kaur
Journal: Mol Ther Date: 2022-02-08 Impact factor: 12.910

3. Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

Authors: Jesse J McClure; Cheng Zhang; Elizabeth S Inks; Yuri K Peterson; Jiaying Li; C James Chou
Journal: J Med Chem Date: 2016-10-26 Impact factor: 7.446

Review 4. Lysine acetylation as drug target in fungi: an underexplored potential in Aspergillus spp.

Authors: Natália Sayuri Wassano; Ariely Barbosa Leite; Franqueline Reichert-Lima; Angelica Zaninelli Schreiber; Nilmar S Moretti; André Damasio
Journal: Braz J Microbiol Date: 2020-03-13 Impact factor: 2.476

5. In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1).

Authors: Amarjeet Kumar; Suman Kumar Dhar; Naidu Subbarao
Journal: J Mol Model Date: 2018-08-14 Impact factor: 1.810

6. Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group.

Authors: Yu Bao; Qihao Xu; Lin Wang; Yunfei Wei; Baichun Hu; Jian Wang; Dan Liu; Linxiang Zhao; Yongkui Jing
Journal: ACS Med Chem Lett Date: 2021-01-05 Impact factor: 4.345

Review 7. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.

Authors: Amila Suraweera; Kenneth J O'Byrne; Derek J Richard
Journal: Front Oncol Date: 2018-03-29 Impact factor: 6.244